Jim Simons Travere Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $62.3 Billion
- Q1 2025
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,702,814 shares of TVTX stock, worth $45.7 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
2,702,814
Previous 2,409,514
12.17%
Holding current value
$45.7 Million
Previous $42 Million
15.39%
% of portfolio
0.08%
Previous 0.07%
Shares
18 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
101MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$150 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$129 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$127 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$84.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$81.1 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.09B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...